To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression
The histopathology is limited-stage small cell lung cancer.
ECOG score 0-2.
Good organ function (no blood transfusions, no hematopoietic stimulating factors, no transfusions of albumin or blood products within 14 days prior to the examination).
It is suitable for patients treated with Trilaciclib combined with etoposide plus cisplatin or carboplatin.
Brain metastases with clinical symptoms require local radiotherapy or hormone therapy.
Active infections require systemic treatment.
Subjects with active, known or suspected autoimmune disease or history of autoimmune disease.
Combined with other tumors.